Price Chart

Executive Summary

Morgan Stanley upgraded Merck & Co., Inc. (MRK) from Equal-Weight to Overweight on August 20, 2026, with a new price target of $179, a massive 54.3% increase from its prior $116 target. The upgrade is part of a two-firm cluster on MRK, with RBC Capital simultaneously downgrading to Sector Perform (PT $150). Morgan Stanley's call is contrarian to the consensus mean target of $137.73 and median of $142, but aligns with the bullish tilt in consensus (69% Buy/Strong Buy). The firm's 55% accuracy on 4,986 calls is below average among covering firms, and its 43% accuracy on 7 MRK calls is also below average. The stock trades at $152.20, already above the consensus mean and median, implying 17.6% upside to Morgan Stanley's new target. Momentum is mixed: 2 upgrades and 1 downgrade in 30 days, with EPS revisions slightly negative for the current quarter (1 up, 5 down in 30 days). Insider selling is heavy, with five sales totaling ~$14.3M in August, including a $10.7M sale by EVP Zachary Jennifer, which diverges from the bullish analyst signal. The bottom line: Morgan Stanley's bold PT hike is a standout, but the firm's below-average track record on MRK and heavy insider selling warrant caution.

Impact Score

Consensus & Targets

Consensus is 69% Buy/Strong Buy (9 strong buy, 16 buy), 31% Hold (11 hold), 0% Sell. This is a strongly bullish consensus, with 25 of 36 analysts recommending buying. Morgan Stanley's upgrade aligns with the majority view but is more aggressive on price target.

Current price: $152.20. Consensus mean target: $137.73 (implied downside of -9.5%). Median: $142 (downside -6.7%). High: $155 (upside +1.8%). Low: $105 (downside -31%). Morgan Stanley's new PT of $179 is the highest among all covering analysts, implying 17.6% upside and sitting well above the consensus mean and median.

Recent Analyst Activity

30-day analyst activity: 2 upgrades (Morgan Stanley, Daiwa Capital) and 1 downgrade (RBC Capital). EPS revisions: current quarter (0q) has 1 up and 5 down in 30 days, with EPS declining from $2.30 to $2.21. Next quarter (+1q) has 2 up and 4 down. Full-year (+1y) has 5 up and 4 down. Overall, estimates are being revised slightly lower for near-term quarters but stable for the full year.

Firm Track Record — Morgan Stanley

Morgan Stanley accuracy: 55% on 4986 calls | avg return: 4.3%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 12 firms with ≥5 scored calls.

Morgan Stanley has a 55% accuracy rate on 4,986 calls overall, with an average return of 4.3%. On MRK specifically, they are 3 for 7 (43% accuracy), below average. Among covering firms, Deutsche Bank leads with 100% accuracy on 2 calls (avg return 9.7%), while Cantor Fitzgerald is worst at 9% on 11 calls (avg return -5.5%). Morgan Stanley's call is contrarian to its own below-average track record on MRK.

Earnings Estimates

Cross-Platform Signals

Insider trades: Five sales totaling ~$14.3M in August, including a $10.7M sale by EVP Zachary Jennifer on Aug 12 and a $1.46M sale by EVP DeLuca Richard R. on Aug 12. No insider buys. This is a strong bearish divergence from the bullish analyst signal. Institutional changes are mixed: Zurich Cantonalbank added 44.7% ($190M), while First Trust Advisors trimmed 42% ($333M). Short interest ratio is 56.8%, indicating elevated bearish positioning. No congressional trades reported.

Investment Themes

Documents Analyzed

Report based on filing metadata.

US Market Status